Basel, Switzerland, February 6, 2019
EsoCap AG and LTS Lohmann Therapy-Systeme AG announced the start of cooperation on industrial development of a unique drug delivery technology for diseases of the upper gastrointestinal tract. This collaboration leverages the collective expertise of a strong partner in the thin film industry with a highly innovative application technology.
“We are particularly pleased to be partnering with LTS, a global leader in the development and manufacture of film technologies for the pharmaceutical industry”, said Isabelle Racamier, EsoCap CEO. “We are committed to working closely with LTS to enter rapidly into a clinical trial in patients suffering from eosinophilic esophagitis. EsoCap technology may be beneficial in at least six indications affecting 370 million patients.”
Under the terms of this cooperation, LTS is working on implementation of its thin film know-how as applied to EsoCap’s unique drug delivery technology for diseases of the upper gastrointestinal tract.
“As a company committed to delivering pharmaceutical solutions based on our thin film technology, we are greatly interested in expanding our technology’s fields of application.”, said Dr. Hanshermann Franke, Senior VP Research and Development at LTS. “We are thrilled by EsoCap’s highly innovative approach in the area of drug delivery to the upper gastrointestinal tract.”
